The delayed effects of phencyclidine enhance amphetamine-induced behavior and striatal c-Fos expression in the rat

Neuroscience

Volumn 91, Issue 4, 1999, Pages 1265-1275

  Turgeon, S M ^a   Roche, J K ^a  

^a AMHERST COLLEGE   (United States)

Author keywords

Amphetamine; Anterior cingulate cortex; C Fos; Phencyclidine; Schizophrenia; Striatum

Indexed keywords

AMPHETAMINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CINGULATE GYRUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; GENE EXPRESSION; GENE INDUCTION; LIMBIC CORTEX; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STRIATE CORTEX;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DRUG SYNERGISM; IMMUNOHISTOCHEMISTRY; MALE; PHENCYCLIDINE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0032903608     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00715-5     Document Type: Article

References (60)

1. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiat. 135:1978;1081-1084.
2. Angrist B., Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv. Biochem. Pharmac. 16:1977;667-680.
3. Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacologia. 72:1980;17-19.
4. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmac. 79:1983;565-575.
5. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Comprehensive Psychiat. 2:1961;269-280.
6. Baruch I., Hemsley D.R., Gray J.A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. nerv. ment. Dis. 176:1988;598-606.
7. Bergeron B., de Montigny C., Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J. Neurosci. 16:1996;1193-1202.
8. Costall B., Marsden C.D., Naylor R.J., Pycock C.J. Stereotyped behavior patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei. Brain Res. 123:1977;89-111.
9. Creese I., Iverson S.D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res. 83:1975;419-436.
10. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiat. 148:1991;1474-1486.
11. Debonnel G. Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J. psychiat. Neurosci. 18:1993;157-172.
12. Deutch A.Y., Tam S.-Y., Freeman A.S., Bowers M.B., Roth R.H. Mesolimbic and mesocortical dopamine activation induced by phencyclidine: contrasting pattern to striatal response. Eur. J. Pharmac. 134:1987;257-264.
13. Ellenbroek B. A. and Cools A. R. (1995) Animal models of psychotic disturbances. In Advances in the Neurobiology of Schizophrenia (eds Den Boer J. A., Westenberg H. G. M. and Praag H. M.), pp. 89-110. John Wiley, New York.
14. Fink J.S., Smith G.P. Relationships between selective denervation of dopamine terminal fields in the anterior forebrain and behavioral responses to amphetamine and apomorphine. Brain Res. 201:1980;107-127.
15. Gao X.-M., Shirakawa O., Du F., Tamminga C.A. Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmac. 241:1993;7-15.
16. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. natn. Acad. Sci. U.S.A. 87:1990;6912-6916.
17. Greenberg B.D., Segal D.S. Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmac. Biochem. Behav. 23:1985;99-105.
18. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmac. 18:1995;237-249.
19. Haroutunian V., Knott P., Davis K.L. Effects of mesocortical dopaminergic lesions upon subcortical dopamine function. Psychopharmac. Bull. 24:1988;341-344.
20. 4 sites in schizophrenic brains. Eur. J. Pharmac. 314:1996;R3-R5.
21. Heresco-Levy U., Javitt D.C., Zukin S.R. The phencyclidine/N-methyl-D-aspartate (PCP/NMDA) model of schizophrenia: theoretical and clinical implications. Psychiat. Ann. 23:1993;135-143.
22. Hondo H., Yonezawa Y., Nakahara T., Nakamura K., Hirano M., Uchimura H., Tashiro N. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633:1994;337-342.
23. Itzhak Y. Pharmacological specifity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites. Life Sci. 42:1988;745-752.
24. Jaber M., Cador M., Dumartin B., Normand E., Stinus L., Bloch B. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and fos immunoreactivity in rat striatal neurons. Neuroscience. 65:1995;1041-1050.
25. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. clin. Psychiat. 9:1987;12-35.
26. Javitt D.C., Zukin S.R. The role of excitatory amino acids in neuropsychiatric illness. J. Neuropsychiat. clin. Neurosci. 2:1990;44-52.
27. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat. 148:1991;1301-1308.
28. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
29. Jentsch J.D., Tran A., Le D., Youngren K.D., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99.
30. Kelly P.H., Seviour P.W., Iverson S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94:1975;507-522.
31. Konradi C., Leveque J.-C., Hyman S.E. Amphetamine- and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J. Neurosci. 16:1996;4231-4239.
32. Kuczenski R., Segal D.S., Aizenstein M.L. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J. Neurosci. 11:1991;2703-2712.
33. LaHoste G.J., Ruskin D.N., Marshall J.F. Cerebrocortical Fos expression following dopaminergic stimulation: D1/D2 synergism and its breakdown. Brain Res. 728:1996;97-104.
34. Largent B.L., Wikstrom H., Snowman A.M., Snyder S.H. Novel antipsychotic drugs share high affinity for σ receptors. Eur. J. Pharmac. 155:1988;345-347.
35. Lillrank S.M., Lipska B.K., Bachus S.E., Wood G.K., Weinberger D.R. Amphetamine-induced c-fos mRNA expression is altered in rats with neonatal hippocampal damage. Synapse. 23:1996;292-301.
36. Luby E.D., Cohen B.D., Rusenbaum G., Gottieb J.S., Kelly R. Study of a new schizophreniamimetic durg - sernyl. Archs Neurol. Psychiat. 81:1959;363-369.
37. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
38. McCullough L.D., Salamone J.D. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res. 577:1992;1-9.
39. Mittleman G., LeDuc P.A., Whishaw I.Q. The role of D1 and D2 receptors in the heightened locomotion induced by direct and indirect dopamine agonists in rats with hippocampal damage: an animal analogue of schizophrenia. Behav. Brain Res. 55:1993;253-267.
40. Moghaddam R. Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog. Neuro-Psychopharmac. biol. Psychiat. 18:1994;859-870.
41. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br. J. Pharmac. 116:1995;2531-2537.
42. Ogawa S., Okuyama S., Araki H., Nakazato A., Otomo S. A rat model of phencyclidine psychosis. Life Sci. 55:1994;1605-1610.
43. Ogawa S., Okuyama S., Araki H., Otomo S. Effect of NE-100, a novel σ receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur. J. Pharmac. 263:1994;9-15.
44. Okuyama S., Ogawa S., Nakazato A., Tomizawa K. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced delayed cognitive dysfunction in rats. Neurosci. Lett. 189:1995;60-62.
45. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic, San Diego.
46. Persico A.M., Schindler C.W., O'Hara B.F., Brannock M.T., Uhl G.R. Brain transcription factor expression: effects of acute and chronic amphetamine and injection stress. Molec. Brain Res. 20:1993;91-100.
47. Porrino L.J., Lucignani G., Dow-Edward D., Sokoloff L. Correlation of dose-dependent effects of acute amphetamine administration on behavior and local cerebral metabolism in rats. Brain Res. 307:1984;311-320.
48. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-76.
49. Robinson T.E., Becker J. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:1986;157-198.
50. Scatton R., Worms P., Lloyd K.G., Bartholini G. Cortical modulation of striatal function. Brain Res. 232:1982;331-343.
51. Sharp J.W. Phencyclidine (PCP) acts at σ sites to induce c-Fos gene expression. Brain Res. 758:1997;51-58.
52. Simpson J.N., Wang J.Q., McGinty J.F. Repeated amphetamine administration induces a prolonged augmentation of phosphorylated cyclase response element-binding protein and fos-related antigen immunoreactivity in rat striatum. Neuroscience. 69:1995;441-457.
53. Sonders M.S., Keana J.F.W., Weber E. Phencyclidine and psychotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action. Trends Neurosci. 11:1988;37-40.
54. Sturgeon R.D., Fessler R.G., Meltzer H.Y. Behavioral rating scale for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur. J. Pharmac. 59:1979;169-179.
55. Toru M., Kurumaji A., Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci. 55:1994;1683-1699.
56. Turgeon S.M., Auerbach A.E., Heller M.A. The delayed effects of phencyclidine (PCP) disrupt latent inhibition in a conditioned taste aversion paradigm. Pharmac. Biochem. Behav. 60:1998;553-558.
57. Turgeon S.M., Blum J.E., Auerbach A.E. Behavioral sensitization to amphetamine is not accompanied by a decrease in the number of c-Fos containing cells in the striatum. Brain Res. 782:1998;329-332.
58. Turgeon S.M., Pollack A.E., Fink J.S. Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. Brain Res. 749:1997;120-126.
59. Wang J.Q., McGinty J.F. Alterations in striatal zif/268, preprodynorphin and preproenkephalin mRNA expression induced by repeated amphetamine administration in rats. Brain Res. 673:1995;263-274.
60. Weiner I., Feldon J. Phencyclidine does not disrupt latent inhibition in rats: implications for animal models of schizophrenia. Pharmac. Biochem. Behav. 42:1992;625-631.